Revelle Aesthetics, Inc. – a VC-backed Silicon Valley MedTech company focused on designing precision technologies that target the root cause of women’s most bothersome aesthetic concerns – has announced the launch of Avéli™, a disruptive new cellulite device. Revelle’s mission is to develop smart aesthetic solutions that deliver meaningful results for women and reliable outcomes for practitioners.
The Company recently introduced Avéli – an innovative FDA-cleared device that reduces the appearance of cellulite on the buttocks and thighs temporarily* in a one-time procedure – at The Aesthetic Society’s annual plastic surgery conference.
“Revelle was born out of ExploraMed, a Silicon Valley incubator known for engineering unique innovations in challenging-to-solve-for therapeutic areas,” shared Caroline Van Hove, President and CEO of Revelle Aesthetics. “Revelle has spent the last few years in stealth mode focusing on deepening our understanding of the underlying anatomy and the challenges that need to be overcome when addressing cellulite. This extensive anatomical and clinical work enabled us to engineer a precision device that identifies and releases the culprit septa causing a cellulite depression and delivers visible and reproducible results that women and physicians want.”
“It has taken many years to understand the etiology of cellulite, in particular the structural cause – the fibrous septa – making it complicated to treat,” explains Michael Kaminer, MD, dermatologist and co-founder of SkinCare Physicians in Boston, Massachusetts. “With the help of the engineering team at Revelle, we confirmed that the septa are a network of fibrous bands versus a singular, perpendicular band, and are significantly more complicated than we appreciated. Building on this knowledge, Avéli not only gives physicians control over identifying and releasing the complex structure of septa that are tethering the skin, but also allows verification of that release in real-time.”
Avéli is a one-time-use disposable device for cellulite designed to be used in a single in-office procedure using a Targeted, Verifiable Subcision™ method. During an advanced minimally invasive procedure with local anesthesia, a provider can treat both the buttocks and thighs for a variety of women across the spectrum of cellulite severity and complexity. Women can experience visible, meaningful results quickly after the procedure, with little-to-no downtime.
“It was exciting to see and hear the buzz around Avéli at The Aesthetic Meeting,” affirms Marina Del Rey, California-based plastic surgeon Grant Stevens, MD, FACS, founder and Medical Director of Marina Plastic Surgery, and past President of The Aesthetic Society. “Avéli is a novel and versatile device that I can offer as a standalone procedure or as part of a treatment plan with other nonsurgical or surgical body procedures.”
Revelle Aesthetics is taking a ‘no nonsense’ approach with the launch of Avéli by being extremely mindful of the frustration and skepticism that exists in this category. The company plans a targeted rollout to cellulite and body treatment experts in the fields of plastic surgery and dermatology. The focus early on is to replicate the compelling patient outcomes from the clinical studies in a real-world environment with the help of our experienced clinician partners.
“I appreciate that Revelle is being very up front in what Avéli does and does not treat. While I can use Avéli to effectively address cellulite dimples, it is not intended to treat laxity or fat,” explains Dr. Jennifer Harrington, plastic surgeon and founder of Harrington Plastic Surgery in Minneapolis, Minnesota. “With up to 90% of women having cellulite, there is a huge need and opportunity for Avéli. Launching just in time for summer, I believe Avéli will be a game-changer, not only for how we address cellulite but also how we approach lower body rejuvenation and the future of aesthetics for women overall.”
Visit MyAveli.com for more information about the procedure and to see patient results. Join the cellulite conversation on Instagram @aveli.
*As demonstrated through three months of observation. Women who participated in the clinical study will be followed out through 12 months post-procedure.